Last reviewed · How we verify
CHF 5993 DPI
CHF 5993 DPI is a dry powder inhaler formulation of a specific drug.
CHF 5993 DPI is a dry powder inhaler formulation of a specific drug. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | CHF 5993 DPI |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of CHF 5993 DPI is not publicly available, but it is believed to work by delivering a specific active pharmaceutical ingredient directly to the lungs.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Cough
- Dyspnea
Key clinical trials
- Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (PHASE3)
- Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers (PHASE1)
- Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF 5993 DPI CI brief — competitive landscape report
- CHF 5993 DPI updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI